Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024

SELL
$0.22 - $0.28 $33 - $42
-150 Reduced 33.04%
304 $0
Q3 2023

Nov 01, 2023

BUY
$0.24 - $0.35 $12 - $18
54 Added 13.5%
454 $0
Q2 2023

Aug 04, 2023

BUY
$0.22 - $0.55 $88 - $220
400 New
400 $0
Q4 2022

Feb 02, 2023

SELL
$0.89 - $58.2 $642 - $42,020
-722 Reduced 72.34%
276 $0
Q3 2022

Nov 04, 2022

SELL
$1.81 - $56.1 $1,648 - $51,107
-911 Reduced 47.72%
998 $1,000
Q2 2022

Aug 03, 2022

SELL
$1.64 - $3.11 $6,204 - $11,765
-3,783 Reduced 66.46%
1,909 $5,000
Q1 2022

May 02, 2022

SELL
$2.6 - $3.3 $1,606 - $2,039
-618 Reduced 9.79%
5,692 $16,000
Q4 2021

Feb 23, 2022

BUY
$3.05 - $7.08 $19,041 - $44,200
6,243 Added 9317.91%
6,310 $19,000
Q2 2021

Aug 12, 2021

BUY
$7.19 - $18.96 $481 - $1,270
67 New
67 $1,000

Others Institutions Holding GTBP

About GT Biopharma, Inc.


  • Ticker GTBP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,557,700
  • Market Cap $96.4M
  • Description
  • GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...
More about GTBP
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.